2nd Quarter - Termination
TIBER CREEK GROUP for ROIVANT SCIENCES, INC.
Firm
Client
Income
$20,000
Expenses
—
Terminated
May 31, 2020
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Development of therapeutics for COVID-19 and other respiratory conditions
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JAMES HEIMBACH | — |
| JONATHON JONES | — |
| MATTHEW LEFFINGWELL | — |
| ANDREW MCKECHNIE | — |
| JENNIFER OLSON | — |
| JEFFREY SHAPIRO | — |
Pharmacy PHA
Development of therapeutics for COVID-19 and other respiratory conditions
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JAMES HEIMBACH | — |
| JONATHON JONES | — |
| MATTHEW LEFFINGWELL | — |
| ANDREW MCKECHNIE | — |
| JENNIFER OLSON | — |
| JEFFREY SHAPIRO | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ROIVANT SCIENCES HOLDINGS LTD. | United Kingdom | United Kingdom | 100.0% | — |
| ROIVANT SCIENCES LTD. | Bermuda | United Kingdom | 100.0% | — |
| ROIVANT SCIENCES GMBH | Switzerland | Switzerland | — | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.